Achaogen, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) exercised an option to provide $60 million to support a Phase III trial of Achaogen's plazomicin ( ACHN-490) to treat Gram-negative...